FDA revising promotion guidances, says Abrams

Share this article:
Tom Abrams
Tom Abrams

The FDA is revising two drug-promotion guidances, CDER Office of Drug Product Promotion director Tom Abrams told a Drug Information Association annual meeting session in June.

FDA's Brief Summary guidance is being re-worked, he said, “based on data analyses of three OPDP social science communication research studies.” Public docket comments were also considered. The other guidance being revised is the Presentation of Risk Information in Promotional Materials guidance. This revision is also based on public comments, Abrams told DIA.

Abrams said he has seen an improvement in voluntary compliance and the quality of healthcare promotions. But “while there has been progress,” he says, “we still have a ways to go.”

Abrams said there has been a lot of interest in how advertising and promotion enforcement will be affected by the Caronia decision, in which the US Court of Appeals for the Second Circuit vacated a criminal conviction of Alfred Caronia, a former Orphan Medical sales rep accused of promoting Xyrem to a doctor for off-label uses.

Abrams said FDA has no plans to change its advertising and promotion enforcement approach in the wake of Caronia.

More generally, he said the decision “does not strike down any of the provisions of the Food, Drug and Cosmetic Act or its implementing regulations.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?